Metraipolis › archive › dc_d89eb2ea18ce

Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort — Europe PMC PMID:42346632

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42346632
DOI: 10.3390/jpm16060321
License (as archived): solo-consultazione
Archived: 2026-10-08T04:03:07.400Z
SHA-256 of the archived text: 8e02151790a2d51970dcf06de2e2d8fa03e9d0efd5799025cbf751281c5853cf
Stable URL of this page: https://metraipolis.com/documento/dc_d89eb2ea18ce

How to cite

Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort — Europe PMC PMID:42346632 — Europe PMC (en), https://europepmc.org/article/MED/42346632 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d89eb2ea18ce (Metraipolis archive dc_d89eb2ea18ce, sha256 8e02151790a2d51970dcf06de2e2d8fa03e9d0efd5799025cbf751281c5853cf)

BibTeX

@misc{dcd89eb2ea18ce,
  title = {Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort — Europe PMC PMID:42346632},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42346632},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d89eb2ea18ce; sha256 8e02151790a2d51970dcf06de2e2d8fa03e9d0efd5799025cbf751281c5853cf},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42346632. Agents can read the archived copy with the MCP tool read_document.